Research Desk Line-up: Aoxing Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / June 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sanofi (NYSE: SNY). The Company announced on June 10, 2017 that diabetes drug Soliqua® 100/33 lowered mean blood sugar levels (HbA1c) by 1.09% to 2.41% after 30 weeks in adult patients with Type-2 diabetes, who were earlier treated with between 15 and 40 units of basal insulin daily. The data was revealed in a post-hoc analysis of data from the LixiLan-L Phase-3 study conducted by the Company where patients were injected with Soliqua® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL. The study had grouped the participants by HbA1c level at screening. The data also revealed that all subgroups reached a mean HbA1c below 7% for the duration of the study. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
Discover more of our free reports coverage from other companies within the Drug Manufacturers - Major industry. Pro-TD has currently selected Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) for due-diligence and potential coverage as the Company announced on May 15, 2017, its financial results for Q3 FY17 which ended on March 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Aoxing Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SNY; also brushing on AXN. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=SNY
http://protraderdaily.com/optin/?symbol=AXN
The Company shared the data on June 10, 2017, during the poster presentation at the American Diabetes Association (ADA) 77th Scientific Sessions held at San Diego, California.
Commenting on the development, Riccardo Perfetti, Vice President, Head of Global Medical Affairs Diabetes, Sanofi said:
“This analysis demonstrated the substantial blood sugar lowering effect that can be achieved with SOLIQUA 100/33, and also its potential to help adults reach HbA1c levels below 7 percent, which is recommended as a treatment goal by bodies such as the American Diabetes Association for many adults with diabetes.”
Snapshot of the data analysis
The data is related to Sanofi's LixiLan-L Pivotal Phase-3 clinical trial which aimed to study the effectiveness of SOLIQUA 100/33 and insulin glargine 100 Units/mL in adult patients whose Type-2 diabetes was not adequately controlled in spite of taking between 15 and 40 units of basal insulin daily, alone or in combination with one or two oral anti-diabetic agents. The study covered 736 adults. The LixiLan-L study indicated that there was a significant reduction in HbA1c levels in patients taking SOLIQUA 100/33 as compared to those patients who were given insulin glargine 100 Units/mL.
The data analysis covered 660 participants over a 30-week period. The participants were divided into three groups based on their HbA1c at screening. The three groups were patients with HbA1c levels ≤8%; patients with HbA1c levels between >8% to ≤9% and patients with HbA1c levels >9%. The ANOVA analysis was used to study the patients from the time of screening till the end of the 30-week period. Least Squares (LS) mean reductions in HbA1c for the SOLIQUA 100/33 treatment groups after 30 weeks were 1.09%, 1.44% and 2.41%, respectively. The mean HbA1c observed for each subgroup was ≤7% with Soliqua 100/33 (6.65%, 6.99% and 6.97% respectively), but >7% with insulin glargine 100 Units/mL alone (7.22%, 7.42% and 7.66%, respectively). All the categories showed that reduced HbA1c levels for patients given SOLIQUA 100/33 was higher compared to those who were given insulin glargine 100 Units/mL.
The side effects recorded in patients continue to be as previously reported at the end of the LixiLan-L clinical trials. The incidence of symptomatic hypoglycemia in patients who were given SOLIQUA 100/33 (40% of patients with 3.0 events/year E/Y) and those who were given insulin glargine 100 Units/mL was similar (42.5% of patients; 4.2 E/Y). Also 10.4% of the patients who were given SOLIQUA 100/33 experienced nausea whereas 3.6% experienced vomiting. Comparatively in patients who were given insulin glargine 100 Units/mL 0.5% experienced nausea and 0.5% experienced vomiting.
About SOLIQUA® 100/33
In November 2016, Sanofi received US Food and Drug Administration (FDA) approval for SOLIQUA® 100/33 and in January 2017 it was launched commercially and was available in US retail pharmacies. In the European Union, it has been approved as SULIQUA® for Type-2 diabetes patients.
SOLIQUA® 100/33 is a prescription daily injection which contains a combination of lixisenatide and insulin glargine (Lantus®) and a GLP-1 receptor agonist. Both medicines are for diabetes and help improve control of blood sugar (glucose) in adults with Type-2 diabetes when used in conjunction with diet and exercise. This medicine is not for patients who are using long-acting (basal) insulin or lixisenatide.
The medicine is also not meant for people with Type-1 diabetes, diabetic ketoacidosis, or people who have gastroparesis (a stomach problem that causes slow emptying). It has not been studied for people who have a history of pancreatitis or has not been studied together with short-acting insulin. The effectiveness and safety of the medicine on patients who are under the age of 18 years is still unknown.
SOLIQUA® 100/33 is to be used only as prescribed by a doctor or healthcare practioner. It can cause severe serious side effects, including severe allergic reactions which could cause swelling of face, lips, tongue, or throat, leading to breathing problems and or difficulty in swallowing, severe rash, itching, rapid heartbeat etc. It could also cause hypoglycemia (low blood sugar), kidney problems, hypokalemia (low potassium levels), and can even cause heart failure in some people.
About Sanofi
Sanofi is a global life sciences Company that discovers, develops and distributes therapeutic solutions focused on patients' needs. Its global business is divided into five verticals - Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare.
Its Diabetes and Cardiovascular unit is committed to and is working to address the diabetes public health concern worldwide through its integrated treatments and medical devices. It has also forged strategic partnerships with other pharma Companies to develop and expand its portfolio of diabetes medicines. It is also working actively with local health authorities and NGOs around the world to improve the diagnosis of diabetes and patient knowledge as well as to train health professionals.
Last Close Stock Review
At the closing bell, on Monday, June 12, 2017, Sanofi's stock dropped 1.31%, ending the trading session at $47.57. A total volume of 1.42 million shares have exchanged hands. The Company's stock price rallied 8.51% in the last three months, 19.61% in the past six months, and 20.71% in the previous twelve months. Moreover, the stock surged 17.63% since the start of the year. The stock is trading at a PE ratio of 23.26 and has a dividend yield of 3.45%. The stock currently has a market cap of $120.93 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
ReleaseID: 465634
